The effect of nandrolone decanoate on bone marrow suppression induced by cytostatic agents.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D007970:Leukopenia / Q000139:chemically induced* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D009277:Nandrolone / Q000494:pharmacology* / Q000627:therapeutic use; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014750:Vincristine; D009277:Nandrolone; D004317:Doxorubicin; D003520:Cyclophosphamide